FDA WARNING_LETTER - Dermacare dba Filler Outlet - November 01, 2025

The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Dermacare dba Filler Outlet on November 3, 2025, following a review of their website. The FDA observed the company introducing misbranded and unapproved new drugs, specifically injectable botulinum toxin products like "Innotox 50u," into interstate commerce. These actions violate several sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act), including 301(a), 301(d), 503(b), 505(a), and 502(f)(1).

The primary issues involve the sale of unapproved drugs that lack FDA evaluation for safety and effectiveness, posing significant consumer risks such as contamination, inconsistent active ingredients, and serious health complications from injectables. Furthermore, these products are misbranded as they are prescription-only drugs offered without adequate directions for layperson use or the supervision of a licensed practitioner. The FDA requires Dermacare dba Filler Outlet to immediately cease offering all unapproved and misbranded drugs for sale to U.S. consumers. The company must conduct a thorough review of its website, product labels, and promotional materials to ensure full compliance with the FD&C Act. A written response detailing specific corrective actions and measures to prevent recurrence is required within 15 working days.